Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 trial update showing safety and efficacy results for intranasal esketamine in treatment-resistant depression, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Spravato (esketamine) (esketamine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Treatment Resistant Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2019-06-12